Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published review analyses for the evaluation of reimbursement applications:
- Reblozyl (luspatercept) for the treatment of myelodysplastic anemia
- Erwinia (chrysanthemum pasha) for the treatment of acute leukemia
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
